Global consumption patterns of combination hypertension medication: An analysis of pharmaceutical sales data from 2010-2021.

Autor:	Jayawardana S; Department of Health Policy, LSE Health, London School of Economics and Political Science, London, United Kingdom., Campbell A; IQVIA Institute for Human Data Science, Parsippany, New Jersey, United States of America., Aitken M; IQVIA Institute for Human Data Science, Parsippany, New Jersey, United States of America., Andersson CE; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America., Mehra MR; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America., Mossialos E; Department of Health Policy, LSE Health, London School of Economics and Political Science, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	PLOS global public health [PLOS Glob Public Health] 2024 Sep 06; Vol. 4 (9), pp. e0003698. Date of Electronic Publication: 2024 Sep 06 (Print Publication: 2024).
DOI:	10.1371/journal.pgph.0003698
Abstrakt:	Hypertension is the most significant risk factor for cardiovascular disease and mortality worldwide, affecting 1.3 billion adults. Global disparities in hypertension control are widening with low- and middle-income countries (LMIC) having the fastest growing rates of hypertension and low rates of control. Treatment for hypertension can be challenging, with multiple drug classes and dosing schedules. Combination antihypertensives have been suggested as a solution for their efficacy and potential to improve adherence. Global consumption of combination and non-combination antihypertensives across 75 countries and 2 regions from 2010 to 2021 was estimated using the IQVIA MIDAS database on pharmaceutical sales. Consumption rates were standardized using Standard Units (SUs) and analysed by high-income (HIC), upper-middle income (UMIC), and LMIC income classification. Global median consumption rate of all antihypertensives per 1000 inhabitants per day increased from 184.78 SUs in 2010 to 325.6 SUs in 2021, with HICs consistently having the highest rates. Median consumption rates of combination and non-combination antihypertensives increased across all country income groups but combination drugs were consumed at a lower rate and proportion. LMICs consumed a higher percentage of combination antihypertensives relative to non-combination (45.5%) than UMICs (24.3%) and HICs (24.4%) in 2021. While combination antihypertensives may be preferred for their potential for increased adherence and effectiveness, their global uptake is inconsistent. HICs consume less combination medication relative to non-combination, despite higher overall consumption rates of antihypertensives. LMICs show increasing use of combination medications, indicating a shift towards their use. Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests. Mandeep R. Mehra reports consulting fees from Abbott, J and J, FineHeart, NupulseCV, Leviticus, Moderna, Second Heart Assist, Cadrenal, Broadview Ventures, Natera, Paragonix, Transmedics and is an Advisory Board member for Janssen and Mesoblast. Allen Campbell and Murray Aitken are employed by IQVIA and do not receive additional fees from pharmaceutical companies or other sources. All other authors have no relevant disclosures. (Copyright: © 2024 Jayawardana et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu